Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this study is to assess the safety and tolerability of 160 mg of subcutaneous (SC) therapy with rilonacept in the prophylaxis of gout flares in subjects on urate lowering therapy.
Critère d'inclusion
- Gout flares